Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Schenk

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Pediatric Blood & Cancer|April 20, 2026
Characteristics and Survival of Patients With Wilms Tumor and Bone Metastases: A SIOP-RTSG 93-01, SIOP 2001, and UK-IMPORT StudyArianna Tagarelli, Rana Dandis, Harm Van Tinteren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2026
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 StudyRhoikos Furtwängler, Rana Dandis, Harm van Tinteren, et al.
Journal of Neuroengineering and Rehabilitation|July 5, 2013
MUNDUS project: MUltimodal neuroprosthesis for daily upper limb supportAlessandra Pedrocchi, Simona Ferrante, Emilia Ambrosini, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
JCO Clinical Cancer Informatics|June 23, 2026
A Harmonized International Database of More Than 10,000 Pediatric Renal Tumor Patients From 30 Years of SIOP-RTSG StudiesPrakriti Roy, Ingrid Schut, Norbert Graf, et al.
Urologic Oncology|June 22, 2025
Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study groupAlissa Groenendijk, Harm van Tinteren, Ronald R de Krijger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocolsAlissa Groenendijk, Harm van Tinteren, Yilin Jiang, et al.
British Journal of Cancer|July 30, 2024
Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG)Hélène Sudour-Bonnange, Harm van Tinteren, Gema L Ramírez-Villar, et al.
Wiener Klinische Wochenschrift|June 14, 2020
Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020) : Statement of the Austrian Society of Pneumology (ASP)Holger Flick, Britt-Madelaine Arns, Josef Bolitschek, et al.
Wiener Klinische Wochenschrift|April 22, 2022
Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP)Horst Olschewski, Ernst Eber, Brigitte Bucher, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Pediatric Blood & Cancer|April 20, 2026
Characteristics and Survival of Patients With Wilms Tumor and Bone Metastases: A SIOP-RTSG 93-01, SIOP 2001, and UK-IMPORT StudyArianna Tagarelli, Rana Dandis, Harm Van Tinteren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2026
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 StudyRhoikos Furtwängler, Rana Dandis, Harm van Tinteren, et al.
Journal of Neuroengineering and Rehabilitation|July 5, 2013
MUNDUS project: MUltimodal neuroprosthesis for daily upper limb supportAlessandra Pedrocchi, Simona Ferrante, Emilia Ambrosini, et al.
Clinical Epigenetics|December 12, 2019
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M van Tilburg, Till Milde, Ruth Witt, et al.
JCO Clinical Cancer Informatics|June 23, 2026
A Harmonized International Database of More Than 10,000 Pediatric Renal Tumor Patients From 30 Years of SIOP-RTSG StudiesPrakriti Roy, Ingrid Schut, Norbert Graf, et al.
Urologic Oncology|June 22, 2025
Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study; A report from the SIOP renal tumor study groupAlissa Groenendijk, Harm van Tinteren, Ronald R de Krijger, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocolsAlissa Groenendijk, Harm van Tinteren, Yilin Jiang, et al.
British Journal of Cancer|July 30, 2024
Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG)Hélène Sudour-Bonnange, Harm van Tinteren, Gema L Ramírez-Villar, et al.
Wiener Klinische Wochenschrift|June 14, 2020
Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020) : Statement of the Austrian Society of Pneumology (ASP)Holger Flick, Britt-Madelaine Arns, Josef Bolitschek, et al.
Wiener Klinische Wochenschrift|April 22, 2022
Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP)Horst Olschewski, Ernst Eber, Brigitte Bucher, et al.
Pageof 14